Replies to post #363935 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

I just linked the article without comment because there's so much of this that I don't understand, in part because of some of the nomenclature.

Also from the IPIX PR:
"The presentation on Brilacidin will be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session."
Non-SARS-CoV-2? Endemic?
The Session Description:
"Abstracts should address: 1. Describe agnostic vaccine platforms to prevent non SARS-CoV-2 viral diseases; 2. New treatment approaches for non SARS-CoV-2 viral diseases; 3. Mitigation strategies to prevent spread /exposure to non SARS-CoV-2 viral diseases."

Meanwhile there is also a "SARS CoV-2 Research Update" Breakout Session, described:
"Abstracts should address on-going research related to the following research areas for SARS CoV-2: Prevention, Detection, Treatment, Enabling Technologies"
No presentation there?


Between the above and your quote from the article ("COVID-related abstracts are for poster presentations only; oral presentations will focus on DoD-sponsored research...") I'm not sure what is being presented.
In addition the article says:
"Abstracts submitted to the MHSRS should represent original, unpublished work. This stipulation means even abstracts presented at other science meetings are ineligible for presentation at MHSRS, with few exceptions. If your abstract has been accepted at other meetings, you'll need to decide which meeting to present your findings."
(The American Society of Virology’s 40th Annual Meeting precedes this meeting.)

Is this presentation to be of previously unpublished DoD-sponsored GMU antiviral Brilacidin research unrelated to Covid? That seems to be the sum of it.

It's ALL intriguing :o)

[olden_grumpini]

Very intriguing connecting of dots!

Here's another dot about the DOD and brilacidin in case others don’t already know. Polymedix received at least 15 research grants or contracts, including several from the Army, for research on “novel defensin-mimetic antimicrobial compounds” (PMX-30063, brilacidin, was their most promising compound). Perhaps this past research helped IPIX get interest on brilacidin as an antiviral? I'm unclear as to why IPIX wouldn't have issued a PR on gov't funding.

Here are a couple articles about Polymedix and DOD funding:
Radnor-based Polymedix earns $1.6 million contract to combat biowarfare pathogens
More Army funding for PolyMedix antimicrobial research

Here's a quote from a Polymedix 2012 press release: PolyMedix Reports Second Quarter 2012 Financial Results:

Defensin-mimetic Research

* PolyMedix recently received a grant from the National Institutes of Health for up to $3 million of funding to develop defensin-mimetic antimicrobial compounds against malaria. This second phase of grant funding follows a successful first phase in which PolyMedix previously received $1 million of funding for anti-malaria research. This work is being conducted in collaboration with Dr. Doron Greenbaum at the University of Pennsylvania.

Previously, PolyMedix has received 15 grants and sponsored research contracts, from the National Institutes of Health, the National Science Foundation, the Defense Threat Reduction Agency, the United States Army, and the United States Navy. PolyMedix continues to strive to support the majority of its research costs through such grant and research contract funding. With this support, PolyMedix has to date created a library of approximately 1,600 defensin-mimetic antimicrobial compounds in multiple distinct chemical series, which are being evaluated for potential use in indications such as malaria, Gram-negative pathogens, food-borne pathogens, fungal pathogens, and for biodefense applications.

[williamssc]

Oral presentations are research other then just covid.